Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR1 pos FGFR2 pos |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR1 pos FGFR2 pos | hepatocellular carcinoma | sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, hepatocellular carcinoma cell lines treated with Fexagratinib (AZD4547) demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320). | 26351320 | |
| FGFR1 pos FGFR2 pos | hepatocellular carcinoma | no benefit | PHA-665752 | Preclinical - Cell culture | Actionable | In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320). | 26351320 |